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Ashesh B. Jani, MD23; Jeffrey M. Kamradt, MD24; Westley Sholes, MPA; and H. Alberto Vargas, MD16
abstract
PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced
prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this
guideline is intended to outline techniques available and provide recommendations on appropriate use of
imaging for specified patient subgroups.
METHODS An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology,
American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological
Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic
review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced
prostate cancer. Representative index cases of various prostate cancer disease states are presented, including
suspected high-risk disease, newly diagnosed treatment-naı̈ve metastatic disease, suspected recurrent disease
after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the
literature from 2013 to August 2018 identified fully published English-language systematic reviews with or
without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared$ 2
imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality.
RESULTS A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews
with or without meta-analysis and 18 primary research articles.
RECOMMENDATIONS One or more of these imaging modalities should be used for patients with advanced
prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate
magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography
[PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
INTRODUCTION
The purpose of this clinical practice guideline is to
provide referring and imaging clinicians (including
medical oncologists, radiation oncologists, urologists,
radiologists, nuclear medicine physicians, and mo-
lecular imagers), other health care practitioners, pa-
tients, and caregivers with recommendations and
future directions regarding optimum imaging for pa-
tients with advanced prostate cancer based on the
best available evidence. The fluid and rapidly evolving
nature of the topic is acknowledged, and although
regulatory approvals of some of the techniques pre-
sented are currently limited, this guideline is intended
to preemptively address the ongoing barrage of studies
that will most certainly transform the landscape for the
management of patients with advanced prostate
cancer. The term advanced prostate cancer encom-
passes a wide swath of patients with different disease
states and clinicopathologic factors, including men
with localized prostate cancer at initial diagnosis with
a high or very high risk of metastasis (as defined re-
cently in an American Urological Association/American
Society of Radiation Oncology/Society of Urologic On-
cology guideline1); men who have been treated and
subsequently present with clinical, biochemical, or ra-
diographic evidence of disease progression; and men
with known metastatic disease either at initial pre-
sentation or after one or more lines of treatment. This
guideline examines the optimal use of imaging for men
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THE BOTTOM LINE
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Endorsed by the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular
Imaging, American Urological Association, American Society for Radiation Oncology, and the Society of Urologic Oncology.
Guideline Question
What are the optimum imaging options that should be offered to patients with advanced prostate cancer?
Target Population
Men with advanced prostate cancer, including newly diagnosed clinical high-risk disease, suspected or confirmed metastatic
disease, recurrent disease, or progressive disease while under treatment.
Target Audience
Medical oncologists, radiation oncologists, urologists, radiologists, nuclear medicine and molecular imaging physicians, other
health care practitioners such as nurses and social workers, patients, and caregivers.
Methods
An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the
medical literature.
Definitions
• Conventional imaging: computed tomography (CT), bone scan, and/or prostate magnetic resonance imaging (MRI).
• Next-generation imaging (NGI): positron emission tomography (PET), PET/CT, PET/MRI, whole-body MRI.
• Advanced prostate cancer: disease states/clinical scenarios described.
• Biochemical recurrence: detectable prostate-specific antigen (PSA) with a subsequent rise after radical prosta-
tectomy or a rise of 2 above nadir PSA achieved after radiotherapy (Phoenix criteria)15; high risk without evidence of
disease locally or distantly on conventional imaging where the definition of undetectable PSA is dependent on the
assay used and may change over time as more-sensitive assays become available; in general, a PSA value , 0.2 ng/mL
has been considered undetectable,1 while lower values (PSA # 0.01 ng/mL) have been advocated when clinically
available.16
Recommendations
Recommendation 1. Imaging is recommended for all patients with advanced prostate cancer. See the recommendation
under clinical question 4 for specific details according to clinical scenario (Type: evidence based, benefits outweigh
harms; Evidence quality: moderate; Strength of recommendation: strong).
Recommendation 2. One or more of the following imaging modalities should be used for patients with advanced prostate
cancer: conventional imaging (defined as CT, bone scan, and/or prostate MRI) and/or NGI (PET, PET/CT, PET/MRI,
whole-body MRI), according to clinical scenario (Type: evidence based, benefits outweigh harms; Evidence quality:
moderate; Strength of recommendation: strong).
Recommendation 3. It is recommended when choosing an imaging modality that disease states and clinical scenarios as
outlined are taken into consideration, as the imaging modality may guide treatment or change clinical treatment
decisions (Type: evidence based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation:
strong).
Newly Diagnosed Clinically High-Risk/Very High-Risk Localized Prostate Cancer
Recommendation 4.1. Conventional imaging negative. When conventional imaging (defined as CT, bone scan, and/or
prostate MRI) is negative in patients with a high risk of metastatic disease, NGI (defined as PET, PET/CT, PET/MRI,
whole-body MRI) may add clinical benefit, although prospective data are limited (Type: informal consensus, benefits/
harm ratio uncertain; Evidence quality: weak; Strength of recommendation: moderate).
Recommendation 4.2. Conventional imaging suspicious/equivocal.When conventional imaging is suspicious or equivocal,
NGI may be offered to patients for clarification of equivocal findings or detection of additional sites of disease, which
could potentially alter management, although prospective data are limited (Type: informal consensus, benefits/harm
ratio uncertain; Evidence quality: weak; Strength of recommendation: moderate).
(continued on following page)
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THE BOTTOM LINE (CONTINUED)
Rising PSA After Prostatectomy and Negative Conventional Imaging (either initial PSA undetectable with subsequent rise or PSA
never nadirs to undetectable)
Recommendation 4.3. Both disease states are indicative of potentially undetected, residual local, locoregional, or
micrometastatic disease, and imaging options are not distinct or different between these scenarios. The goal of therapy
and the potential use of salvage local therapies in these scenarios should guide the choice of imaging. For men who are
not candidates or are unwilling to receive salvage local or regional therapy, additional NGI should not be offered (Type:
informal consensus, benefits/harms ratio uncertain; Evidence quality: low; Strength of recommendation: moderate).
Recommendation 4.4. For men for whom salvage radiotherapy is contemplated, NGI should be offered (PSMA imaging
[where available]; 11C-choline or 18F-fluciclovine PET/CT; or PET/MRI, whole-body MRI, and/or 18F-NaF PET/CT) as
they have superior disease detection performance characteristics and may alter patient management (Type: evidence
based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Rising PSA After Radiotherapy and Negative Conventional Imaging
Recommendation 4.5. For men in whom salvage local or regional therapy is not planned or is inappropriate, there is little
evidence that NGI will alter treatment or prognosis. The role of NGI in this scenario is unclear and should not be offered,
except in the context of an institutional review board–approved clinical trial (Type: informal consensus, benefits/harms
ratio uncertain; Evidence quality: intermediate; Strength of recommendation: moderate).
Recommendation 4.6. For men for whom salvage local or regional therapy (eg, salvage prostatectomy, salvage ablative
therapy, or salvage lymphadenectomy) is contemplated, there is evidence supporting NGI for detection of local and/or
distant sites of disease. Findings on NGI could guidemanagement in this setting (eg, salvage local, systemic or targeted
treatment of metastatic disease, combined local andmetastatic therapy). PSMA imaging (where available), 11C-choline
or 18F-fluciclovine PET/CT or PET/MRI, whole-body MRI, and/or 18F-NaF PET/CT have superior disease detection
performance characteristics compared with conventional imaging and alter patient management, although data are
limited (Type: evidence based, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation:
moderate).
Metastatic Prostate Cancer at Initial Diagnosis or After Initial Treatment, Hormone Sensitive
Recommendation 4.7. In the initial evaluation of men presenting with hormone-sensitive disease with demonstrable
metastatic disease on conventional imaging, there is a potential role for NGI to clarify the burden of disease and
potentially shift the treatment intent from multimodality management of oligometastatic disease to systemic anticancer
therapy alone or in combination with targeted therapy for palliative purposes, but prospective data are limited (Type:
informal consensus, benefits/harms ratio uncertain; Evidence quality: intermediate; Strength of recommendation:
moderate).
Nonmetastatic Castration-Resistant Prostate Cancer
Recommendation 4.8. For men with nonmetastatic castration-resistant prostate cancer (CRPC), NGI can be offered only if
a change in the clinical care is contemplated. Assuming patients have received or are ineligible for local salvage
treatment options, NGI may clarify the presence or absence of metastatic disease, but the data on detection capabilities
of NGI in this setting and impact on management are limited (Type: consensus, benefits/harms ratio uncertain;
Evidence quality: weak; Strength of recommendation: moderate).
Metastatic CRPC
Recommendation 4.9. PSA progression. As recommended by the Prostate Cancer Working Group 3 consensus statements,
PSA progression alone for men on treatment of metastatic CRPC should not be the sole reason to change therapy.
Conventional imaging can be used for initial evaluation of PSA progression and should be continued to facilitate
changes/comparisons and serially to assess for development of radiographic progression (Type: informal consensus,
benefits/harms ratio uncertain; Evidence quality: intermediate; Strength of recommendation: strong).
Recommendation 4.10. The use of NGI in this cohort is unclear, with a paucity of prospective data. When a change in
clinical care is contemplated, in an individualized manner, and there is a high clinical suspicion of subclinical
metastasis despite negative conventional imaging, the use of NGI could be contemplated, especially in the setting of
a clinical trial (Type: informal consensus, benefits/harms ratio uncertain; Evidence quality: insufficient; Strength of
recommendation: weak).
(continued on following page)
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Prostate cancer is the most common nondermatologic
cancer in men. In 2019, it was estimated that there would
be 174,650 new cases in the United States, and in spite of
advances in diagnosis and treatment, an estimated 31,620
deaths would occur.2 In addition to its prevalence, prostate
cancer poses unique challenges, including a distinct
clinical disease state characterized by an elevated serum
prostate-specific antigen (PSA) consistent with recurrent
disease without findings of metastases on historically
conventional imaging studies and difficulty in monitoring
patients with metastatic bone disease due to the poor test
characteristics of conventional bone imaging. For these
reasons, coupled with increasing evidence for local salvage
therapy or metastasis-directed therapy or increasingly ef-
fective systemic therapies that have been shown to be
beneficial ever earlier in the natural history of the disease,
there is great interest in identifying better imaging strategies
to inform the optimum management for patients with ad-
vanced prostate cancer.
The predilection for prostate cancer to metastasize to
bone and lymph nodes requires both bone and soft tissue
imaging techniques to assess for staging and to monitor
for response to therapy and progression of disease.
Conventional standard imaging modalities include
99mTc-labeled methylene diphosphonate (99mTc-MDP)
bone scan and computerized tomography (CT) or
magnetic resonance imaging (MRI). The relatively poor
specificity of 99mTc-MDP relates to the fact that MDP
adsorbs onto the crystalline hydroxyapatite mineral of
bone and is not prostate cancer–specific, thus providing
only an indirect measure of tumor activity based on
osteoblastic activity in the tumor microenvironment. In
addition, the interpretation of a bone scan is subjective,
relying on manual assessments of lesion number, size,
and intensity. Such subjective assessments are prob-
lematic in the setting of clinical trials and lead to difficulty
in accurately interpreting treatment effects. Patients
treated with effective therapy can have paradoxically
worsening scans in the face of response to treatment.3
Standard criteria have been developed to standardize
bone scan interpretation and to distinguish response
from progression.4,5 These semiquantitative criteria have
been shown to be feasible, have demonstrated in pro-
spective studies to correlate with survival, and have been
recognized as clinically relevant to warrant their use by
regulatory authorities for drug approval.6-8 In addition,
quantitative tools for the assessment of bone scan data
have been developed, including the automated bone
scan index (BSI), which represents the total tumor
burden as the fraction of the total skeleton weight.9-11
These quantitative tools improve bone scan interpretation
but are still subject to the relatively poor specificity of
99mTc-MDP in patients with metastatic bone disease, the
inability to detect nodal and visceral metastatic disease,
and the poor ability of 99mTc-MDP and CT or MRI to detect
metastatic disease in patients with early biochemical
recurrence.
In the same way that molecularly targeted therapies have
transformed decision making of many diseases, advances
in nuclear medicine and molecular imaging are poised to
re-invent the way in which we diagnose, stage, and monitor
response to therapy in patients with prostate cancer. These
next-generation imaging (NGI) modalities promise im-
proved diagnostic accuracy for staging prostate cancer,
especially at lower tumor burdens. New radiopharma-
ceuticals coupled to prostate cancer–specific targets, such
as prostate-specific membrane antigen (PSMA), are de-
fined in this guideline as external domain PSMA-binding
ligands labeled with the positron emission tomography
(PET)–emitters 68Ga and 18F, exclusive of the PSMA anti-
body capromab pendetide that binds the internal domain of
PSMA. These have demonstrated improvements in the
sensitivity for the detection of metastatic disease and the
monitoring of a treatment effect in patients with advanced
THE BOTTOM LINE (CONTINUED)
Recommendation 4.11. Radiographic progression on conventional imaging. In men with metastatic CRPC with clear
evidence of radiographic progression on conventional imaging while on systemic therapy, NGI should not be routinely
offered. NGI may play a role if performed at baseline to facilitate comparison of imaging findings/extent of progression of
disease (Type: consensus, benefits/harms ratio uncertain; Evidence quality: insufficient; Strength of recommendation:
moderate).
Additional Resources
More information, including a Data Supplement with additional evidence tables, slide sets, and clinical tools and resources, is
available at www.asco.org/genitourinary-cancer-guidelines. The Methodology Manual (available at www.asco.org/guideline-
methodology) provides additional information about the methods used to develop this guideline. Patient information is
available at www.cancer.net.
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients
should have the opportunity to participate.
4 © 2020 by American Society of Clinical Oncology
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prostate cancer compared with conventional imaging.
The recent US Food and Drug Administration (FDA)
approvals of 11C-choline and 18F-fluciclovine for PET
imaging in men with a suspected prostate cancer re-
currence based on an elevated PSA following prior
treatment represent watershed moments in the devel-
opment of novel imaging tools for advanced prostate
cancer.12
While patients and clinicians may find additional imaging,
especially NGI, attractive for advanced prostate cancer in
a variety of clinical states, there are several disadvantages
associated with their use. These NGI modalities are costly
and are not routinely covered by all third-party payers in
the United States. Their routine use could significantly
increase overall expenditure for prostate cancer care.
While the NGI modalities have excellent sensitivity to
detect low-burden disease, false-positive results may
lead to incorrect patient management in some patients.
Moreover, the presence of NGI-detected lesions may
trigger additional procedures, imaging modalities, and
invasive biopsies, which carry risks and additional cost in
addition to mental burden and uncertainty for patients.
Figure 1 provides the imaging algorithm for high/very high-
risk disease at initial presentation (per National Com-
prehensive Cancer Network). Figure 2 provides the im-
aging algorithm for patients with rising PSA after local
treatment.
Another important consideration is concern for the Will
Rogers phenomenon, which may ensue when patients
who are classified as nonmetastatic with conventional
imaging become reclassified as metastatic after
NGI. This may alter treatment decisions with unknown
consequences on the overall disease course.13 The
Will Rogers phenomenon also makes comparison
with historical standards and controls very difficult,
with the risk of artifactual changes in stage-specific
survival.14
This guideline addresses the goals of imaging in ad-
vanced prostate cancer, considering conventional im-
aging techniques and newer NGI modalities, as well as
unmet needs, the potential impact of imaging according
to different advanced prostate cancer clinical disease
states, and the type of imaging that is most appropriate in
each scenario. The guideline focuses on appropriate
utility of imaging for advanced prostate cancer and not
on treatment decisions; any discussion of treatment
decisions are given in the context of the impact of im-
aging on clinical decision making. Evaluation of treat-
ment options and treatment decisions are beyond the
scope of this guideline.
GUIDELINE QUESTIONS
This clinical practice guideline addresses four overarching
clinical questions:
1. What is the goal of imaging in advanced prostate
cancer?
2. What imaging techniques are available for imaging
advanced prostate cancer?
3. What are the unmet needs and potential impact of
imaging according to different advanced prostate
cancer disease states?
4. When and what type of imaging is appropriate in each
scenario?
The recommendations are framed according to these
clinical scenarios:
A. Newly diagnosed clinically high-risk/very high-risk
prostate cancer
i. Conventional imaging negative
ii. Conventional imaging suspicious/equivocal
B. Rising PSA after prostatectomy and negative
conventional imaging
i. Initial PSA undetectable with subsequent rise
















FIG 1. Imaging algorithm for high/very high-risk disease at initial
presentation (per National Comprehensive Cancer Network
[NCCN]). (*) Suspicious findings on NGI would influence treatment
decisions in patients with advanced prostate cancer and negative
conventional imaging, opening the scope for multimodality treat-
ment of primary and oligometastatic disease or systemic therapy for
more extensive metastatic states, although prospective data are
limited. (†) There is enthusiasm for the potential added value of
PSMA PET/CT and PET/MRI for the assessment of the local and
metastatic extent of prostate cancer in this context, although PSMA
imaging is not currently FDA approved and should thus be only
performed as part of a clinical trial or other controlled research
setting. (‡) NGI could offer clinical benefit in this scenario by
redefining the true extent of disease and shifting treatment decisions
accordingly, although prospective data in this context are limited.
BS, bone scintigraphy; CT, computed tomography; mpMRI, mul-
tiparametric magnetic resonance imaging; NGI, next-generation
imaging; PET, positron emission tomography; PSMA, prostate-
specific membrane antigen; WB, whole body.
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C. Rising PSA after radiotherapy and negative conven-
tional imaging
D. Metastatic prostate cancer at initial diagnosis or after
treatment, hormone sensitive




ii. Radiographic progression on conventional imaging
METHODS
Guideline Development Process
This systematic review–based guideline product was de-
veloped by a multidisciplinary Expert Panel comprising
members from all the partner organizations (herein, the
Expert Panel), which included a patient representative and
an ASCO guidelines staff member with health research















































FIG 2. Imaging algorithm for patients with rising prostate-specific antigen (PSA) after local treatment. (*) For men for whom salvage local
therapy (e.g. salvage radiation, salvage prostatectomy) is an option, there is evidence supporting the use of NGI to assess local or distant
sites of disease, which may guide therapy away from salvage local therapy if indicative of distant metastatic disease. (†) There is en-
thusiasm for the potential added value of PSMA PET/CT and PET/MRI for the assessment of the local and metastatic extent of prostate
cancer in this context, although PSMA imaging is not currently FDA approved and should thus be only performed as part of a clinical trial or
other controlled research setting. Mets, metastatic disease; mpMRI, multiparametric magnetic resonance imaging; NGI, next-generation
imaging; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; WB, whole body.
6 © 2020 by American Society of Clinical Oncology
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The Expert Panel met in person several times as well as via
teleconference and/or webinar and corresponded through
e-mail. Based upon the consideration of the evidence,
the authors were asked to contribute to the development
of the guideline, provide critical review, and finalize the
guideline recommendations. The guideline recom-
mendations were sent for an open comment period of
2 weeks, allowing the public to review and comment on
the recommendations after submitting a confidentiality
agreement. These comments were taken into consid-
eration while finalizing the recommendations. Mem-
bers of the Expert Panel were responsible for reviewing
and approving the penultimate version of guideline,
which was then circulated for external review and
submitted to Journal of Clinical Oncology (JCO) for
editorial review and consideration for publication. All
ASCO guidelines are ultimately reviewed and approved
by the Expert Panel and the ASCO Clinical Practice
Guideline Committee (CPGC) prior to publication. All
funding for the administration of the project was pro-
vided by ASCO.
The recommendations were developed by using a sys-
tematic review (2013 through September 2017 and then
updated in August 2018) of systematic reviews with or
without meta-analysis, phase III randomized clinical trials
(RCTs), comparative nonrandomized studies, and clinical
experience. Articles reporting on other study designs were
considered if they included outcomes, interventions, or
comparisons unavailable elsewhere. Articles were selected
for inclusion in the systematic review of the evidence based
on the following criteria:
• Population: men with advanced prostate cancer
• Fully published or recent meeting presentations
of English-language systematic reviews with or
without meta-analyses, reports of rigorously con-
ducted phase III RCTs that compared two or more
imaging modalities, and noncomparative studies
that report on the efficacy of a single imaging
modality
• Reported on a minimum number of patients (. 50)
Articles were excluded from the systematic review if they
were (1) meeting abstracts not subsequently published in
peer-reviewed journals; (2) editorials, commentaries, let-
ters, news articles, case reports, or narrative reviews; or (3)
published in a non-English language. The guideline rec-
ommendations are crafted, in part, using the Guidelines
Into Decision Support (GLIDES) methodology and ac-
companying BRIDGE-Wiz software.17 In addition, a guide-
line implementability review is conducted. Based on the
implementability review, revisions were made to the draft
to clarify recommended actions for clinical practice (see
Data Supplement 5: Implementability Survey Results).
Ratings for the type and strength of recommendation,
evidence, and potential bias are provided with each
recommendation.
Detailed information about the methods used to develop
this guideline is available in the Methodology Manual at
www.asco.org/guideline-methodology. Other information
may be found in the Data Supplement, including the
clinical questions (Data Supplement 1), the search strategy
(Data Supplement 2), the QUORUM diagram (Data
Supplement 3), the study quality assessment (Data Sup-
plement 4A), and the study risk of bias assessment (Data
Supplement 4B).
The ASCO Expert Panel and guidelines staff will work with
co-chairs to keep abreast of any substantive updates to the
guideline. Based on formal review of the emerging litera-
ture, ASCO will determine the need to update. This is the
most recent information as of the publication date.
Guideline Disclaimer
The Clinical Practice Guidelines and other guidance
published herein are provided by the American Society of
Clinical Oncology, Inc. (ASCO) to assist providers in clinical
decision making. The information herein should not be
relied upon as being complete or accurate, nor should it be
considered as inclusive of all proper treatments or methods
of care or as a statement of the standard of care. With the
rapid development of scientific knowledge, new evidence
may emerge between the time information is developed
and when it is published or read. The information is not
continually updated and may not reflect the most recent
evidence. The information addresses only the topics spe-
cifically identified therein and is not applicable to other
interventions, diseases, or stages of diseases. This in-
formation does not mandate any particular course of
medical care. Further, the information is not intended to
substitute for the independent professional judgment of the
treating provider, as the information does not account for
individual variation among patients. Recommendations
reflect high, moderate, or low confidence that the rec-
ommendation reflects the net effect of a given course of
action. The use of words like “must,” “must not,” “should,”
and “should not” indicates that a course of action is rec-
ommended or not recommended for either most or many
patients, but there is latitude for the treating physician to
select other courses of action in individual cases. In all
cases, the selected course of action should be considered
by the treating provider in the context of treating the in-
dividual patient. Use of the information is voluntary. ASCO
provides this information on an “as is” basis and makes no
warranty, expressed or implied, regarding the information.
ASCO specifically disclaims any warranties of merchant-
ability or fitness for a particular use or purpose. ASCO
assumes no responsibility for any injury or damage to
persons or property arising out of or related to any use of this
information, or for any errors or omissions.
Guideline and Conflicts of Interest
The Expert Panel was assembled in accordance with
ASCO’s Conflict of Interest Policy Implementation
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for Clinical Practice Guidelines (“Policy,” found at
http://www.asco.org/rwc). All members of the Expert Panel
completed ASCO’s disclosure form, which requires dis-
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RESULTS
Evidence Overview
A total of 35 articles comprising 17 systematic reviews18-34
with or without meta-analysis and 18 primary research
articles35-52 met eligibility criteria and form the evidentiary
basis for the guideline recommendations. Table 1 provides
a brief description of each. Other articles were brought in for
discussion purposes as warranted.
Systematic Reviews
The 17 systematic reviews18-34 underwent evaluation of
their pooled results from studies published between 1998
and 2017. Eight reviews19,23,24,26,28,30,32,33 compared vari-
ous PET radiopharmaceuticals labeled with 18F or 11C;
three reviews18,20,22 reported on 68Ga-PSMA binding ligand
PET alone using various radiopharmaceuticals; two
reviews21,34 compared PET/CT using various radiophar-
maceuticals with MRI; two reviews25,31 reported on 68Ga-
PSMA binding ligand PET and MRI alone using various
radiopharmaceuticals; and two27,29 reported on a pooled
analysis that included 11C PET/CT, MRI, bone single-
photon emission computed tomography (SPECT), and
bone scintigraphy with various radiopharmaceuticals.
Eleven of these reviews18,19,21,22,24,25,27-29,32,34 reported on
recurrence, staging, or restaging, five20,23,26,30,33 reported
on diagnostic utility, and one31 reported on the results of
pooling outcomes related to determining extraprostatic
extension and seminal vesicle involvement. Table 1 pro-
vides more detail.
Primary Research Articles
The 18 primary research articles35-52 obtained reported on
studies published between 201452 and 201835 that
accrued patients between 2007 and 2017 (six
articles38,41,44,47,48,51 did not report on the years the study
was open to accrual). Seven of these articles37,38,44,48-50,52
used a prospective design, and 11 articles35,36,39-43,45-47,51
were retrospective studies. Five of these articles35,36,38,40,43
reported on studies investigating PSMA binding li-
gand imaged with PET (v other PSMA binding ligands
imaged with PET, histology, or other end points), eight
articles37,39,41,42,45,46,49,51 reported on PSMA binding ligand
with PET imaging modalities compared with PET/CT or
PET/MRI alone, and five articles44,47,48,50,52 reported on
18F or 11C PET/CT. As no pooling was performed, studies
that were also included in any of the previously summa-
rized systematic reviews were retained and are reported
on. Table 1 provides more detail.
Study Quality Assessment
Study design aspects related to individual study quality,
strength of evidence, strength of recommendations, and
risk of bias were assessed. Findings were that the evidence
obtained was a representative body of literature that rec-
ommendations could be based on. For the systematic
reviews, the risk of bias was lower than that of the primary
articles, mostly due to the study designs used in assess-
ments of diagnostic utility (predominantly retrospective
designs with within-group comparisons). See Data Sup-
plement 4A (Study Quality Assessment, systematic reviews
with or without meta-analysis) and Data Supplement 4B
(Study Risk of Bias Assessment, primary studies) for the
complete results of the quality assessment.
Study Results
Systematic reviews. Seventeen systematic reviews18-34
were obtained, and the main findings (Table 2) include
the following:
• In a systematic review comprising 56 studies and
7,329 patients published between 2005 and 2015, Liu
et al23 found 18F-fluorocholine (FCH) PET/CT superior
to 11C-choline, 11C-acetate, and 18F-fludeoxyglucose
(FDG) for both sensitivity and specificity in the initial
detection of prostate cancer.
• Treglia et al,28 in a systematic review comprising 14
studies and 1,869 patients published between 2008
and 2013, found 18F-choline or 11C-choline PET/CT
detection rates were affected by PSA doubling times
and rising PSA velocity, and these two factors should
be taken into account when deciding which patients
are appropriate for restaging with choline PET/CT.
• In a systematic review of 47 studies involving 3,167
patients published between 1998 and 2013, von
Eyben et al26 found either 11C-choline PET/CT or
18F-choline PET/CT informative for recurrence de-
tection in patients with PSA levels between 1 and
50 ng/mL. Performing either test also resulted in
a change to the treatment plan in 41% of patients (381
of 938), while 25% (101 of 404) experienced a com-
plete PSA response.
• Mohsen et al,30 in a systematic review of 25 studies
(number of patients not reported), reported pooled
sensitivity of 75.1% (95% CI, 69.8% to 79.8%) and
pooled specificity of 75.8% (95% CI, 72.4% to 78.9%)
in the detection of initial prostate cancer and a pooled
sensitivity of 64% (95% CI, 59% to 69%) and pooled
8 © 2020 by American Society of Clinical Oncology
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specificity of 93% (95% CI, 83% to 98%) for the
detection of recurrent disease with 11C-acetate PET. It
also found recurrence detection was higher for pa-
tients following surgery and/or radiotherapy and for
patients with PSA at . 1 ng/mL at relapse.
• Umbehr et al,29 in a systematic review of 44 studies
including 2,293 patients in which 29 studies were
pooled, found both 11C-choline PET and 18F-choline
PET to be useful in restaging patients with biochemical
recurrence to determine the best treatment plan.
• In a systematic review of 15 studies involving 1,256
patients, von Eyben et al20 found 68Ga-PSMA PET/CT
to have utility in the detection of disease recurrence for
patients with rising PSA after radical prostatectomy
with PSA levels , 1.0 ng/mL.
• Fitzpatrick et al,18 in a systematic review of 24 studies
involving 2,408 patients, found 68Ga-PSMA PET/CT
associated with good sensitivity (33% to 93%) and
high specificity (. 99%). The likelihood of detection
was found to increase with rising PSA levels and at low
PSA levels, was greater than that of current choline
tracers. Early detection of recurrence does allow for
changes to any follow-up treatment plan. The authors
note that detection may be affected by tracer trapping,
androgen deprivation therapy (ADT), and levels of
PSMA expression.
• In a systematic review of 18 cohort studies involving
2,219 patients, von Eyben et al19 found no difference
in detection rates between 11C-choline PET/CT and
18F-FCH PET/CT in patients with suspected recurrence
(P = .26).
• Fanti et al,24 in a systematic review of 29 diagnostic
studies involving 2,686 patients, found 11C-choline
PET/CT to have high accuracy and good sensitivity
(89%) and specificity (89%) to detect local and/or
distant recurrence in previously treated patients with
prostate cancer.
• In a systematic of review of 19 studies involving 1,555
patients, Evangelista et al32 found both 18F-choline PET
or 11C-choline PET or PET/CT to have high pooled
sensitivity (81.8%; 95% CI, 77.9% to 85.2%) and
specificity (91.4%; 95% CI, 88.3% to 93.9%) to detect
local and/or distant recurrence in previously treated
patients with prostate cancer.
• In a systematic review of 16 studies involving 1,447
patients (including 23 controls), Alfarone et al34 found
multiparametric MRI (mpMRI) superior to 18F-choline
or 11C-choline PET/CT in detecting local recurrence in
patients with low PSA and with small-diameter lesions.
• Ren et al,21 in a systematic review of 6 studies involving
251 patients, found 18F-fluciclovine PET/CT to have
high sensitivity (88%) and acceptable specificity
(67%) to detect prostate cancer recurrence.
• Shen et al,27 in a systematic review of 18 studies in-
volving 1,102 patients, found MRI superior to
11C-choline PET/CT, SPECT, and bone scintigraphy in
the detection of bone metastases on a per-patient
basis but found PET/CT to be superior to bone
SPECT and bone scintigraphy on a per-lesion basis,
with a higher diagnostic odds ratio and maximum
sensitivity and specificity scores (Q*).
• In a systematic review of 7 studies involving 603 pa-
tients, Silva et al31 found 1.5-T MRI to have low sen-
sitivity (49%) and specificity (58%) when used for the
diagnosis and staging of prostate cancer but that
specificity increased when used to determine seminal
vesicle invasion (96%) and extraprostatic extension
(82%), while sensitivity remained low for both (45%
and 49%, respectively).
• In a systematic review of 18 studies (10 of which were
pooled) involving 441 patients, Evangelista et al33
found 11C-choline PET/CT or 18F-choline PET/CT to
have low pooled sensitivity (0.43; 95% CI, 0.33 to
0.53) but high specificity (0.95; 95% CI, 0.91 to 0.97)
in the detection of lymph node metastases prior to
surgery in patients with prostate cancer.
• In a systematic review of 75 studies involving 5,681
patients, de Rooij et al25 foundMRI (diffusion-weighted
[DW] imaging, dynamic contrast enhanced [DCE]) to
have high specificity but low sensitivity for staging local
prostate cancer. Use of an endorectal coil demon-
strated no increase in detection rates for extracapsular
extension but did demonstrate higher sensitivity for
detecting seminal vesicle involvement.
• In a systematic review of 16 studies involving 1,309
patients, Perera et al22 found 68Ga-PSMA PET to have
superior sensitivity and specificity compared with
choline-based PET imaging options and that rising
PSA values and positive 68Ga-PSMA PET results are
correlated.
Primary research articles. Eighteen primary research
articles35-52 were obtained. Full details are provided in
Table 3:
• Three studies35,36,38 investigated the role of the PSMA
binding ligand 99mTc-MIP-1404 imaged with whole-
body planar and SPECT/CT compared with histology,
and one of these38 compared the results of both
against MRI findings. The detection rates with 99mTc-
MIP-1404 whole-body planar and SPECT/CT were
found to vary with PSA level in one study,36 with higher
PSA being associated with higher detection rates. In
this same study, ADT was also associated with higher
detection rates (ADT positive, 86%; ADT negative,
71%; P, .001). The study that compared 99mTc-MIP-
1404 SPECT/CT with MRI found higher detection rates
for SPECT/CT (SPECT/CT, 94%; MRI, 86%).38
• Seven37,39,40,42,43,46,51 studies reported on PSMA
binding ligand 68Ga PET/CT. Two40,43 reported on
PSMA binding ligand 68Ga imaged with PET, and
five37,39,42,46,51 reported on PSMA binding ligand
68Ga imaged with PET in comparison with PET/CT,
20 © 2020 by American Society of Clinical Oncology
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PET/MRI, or mpMRI. Einspieler et al,40 in a study of
the PSMA binding ligand 68Ga imaged with PET/CT,
found that the detection rate increased with both
PSA and with ADT (PSA 2 to , 5 ng/mL, 81.8% v
PSA 5 to , 10 ng/mL, 95.3% v PSA $ 10 ng/mL,
96.8%; P = .038) and ADT (ADT positive, 97.7% v;
ADT negative, 86.3%; P = .038). Two studies37,43
reported that changes to the treatment plan were
made based on the results, with the study by
Albisinni et al43 reporting changing 76% (99 of 131) of
the planned treatments and the study by Habl et al37
reporting changing the staging of 43% of patients and
59% of patients having a change made to the radiation
treatment plan due to 68Ga-PSMA PET/CT outcomes.
For detection of prostate cancer, the study reported by
Freitag et al39 found equivalent rates between 68Ga-
PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI (PET/
CT, 7.6%; PET/MRI, 7.6%) but found both to be inferior
to mpMRI (15.1%; P = .004). The two 68Ga-HBED-CC
studies reported by Berliner et al42 and Ceci et al51 both
found that detection rates increased with PSA. For
Berliner et al, this difference was significant at all PSA
levels (P , .05), and for Ceci et al, while reporting an
overall detection rate of 74.2%, having a positive PET
scan was associated with higher PSA rates and faster
PSA doubling times, and negative PET scans were
associated with the reverse. Of these 7 studies, only
Pfister et al46 reported on measures of diagnostic utility
with 68Ga-HBED-CC being associated with higher
sensitivity (86.9% v 71.2%), specificity (93.1% v
86.9%), accuracy (91.9% v 82.5%), positive pre-
dictive value (PPV; 75.7% v 67.3%), and negative
predictive value (NPV; 96.6% v 88.8%) compared
with 18F-fluoroethylcholine PET/CT, but only accu-
racy and NPV were statistically different at P , .05.
• One study, reported by Rahbar et al,45 examined ra-
dionuclide therapy with the PSMA binding ligand 177Lu
617 followed by 68Ga-PSMA PET to confirm PSMA
expression and found that 64% of patients (53 of 82)
experienced a PSA decline (31% experienced a . 50%
decline in PSA).
• One study, reported by Larbi et al,49 examined whole-
body MRI/DW imaging in the detection of oligometa-
static disease (defined in that study as # 3 synchro-
nous lesions) for treatment planning and found 28% of
all patients with metastatic and hormone-naive pros-
tate cancer were oligometastatic and that 50% of
patients with metastatic CRPC were oligometastatic.
• Six41,44,47,48,50,52 reported on 18F with various radio-
tracers against other modalities. The study by Akin-
Akintayo et al,44 in a comparison of 18F-fluciclovine
PET/CT pre– and post–radiation treatment decision,
reported a detection rate of 81%, while 40.5% of
patients experienced a change in their treatment plan
after PET/CT (P, .001). The study by Odewole et al,47
in a comparison between 18F-fluciclovine PET/CT and
CT alone, reported a detection rate of 77.4% with PET/
CT versus 18.9% with CT alone (P, .05). Five studies
reported on measures of diagnostic utility. The study
by Odewole et al,47 in a comparison between
18F-fluciclovine PET/CT and CT alone, found signifi-
cantly higher sensitivity, accuracy, PPV, and NPV (all
P, .05) associated with 18F-fluciclovine PET/CT in the
prostate/bed, while CT alone reported significantly
higher specificity in the prostate/bed. For extrapro-
static disease, 18F-fluciclovine PET/CT in comparison
with CT alone had significantly higher sensitivity and
NPV (P , .05), borderline higher accuracy (P = .05),
and similar high specificity and PPV of 100%, re-
spectively. The study by Dietlein et al,41 in a compar-
ison between 2 PSMA binding ligands (18F-DCFPyL
PET/CT and 68GA-HBED-CC PET/CT), reported sen-
sitivity of 88% with 18F-DCFPyL PET/CT v 66% with
68Ga-HBED-CC PET/CT for PSA values , 3.5 mg/L
(P, .05). The study by Nanni et al,48 in a comparison
between 18F-fluciclovine PET/CT and 11C-choline PET/
CT, reported superior sensitivity, specificity, accuracy,
PPV, and NPV associated with fluciclovine PET/CT
over choline PET/CT (P values not reported). In
a comparison between 18F-choline PET/CT and whole-
bodyMRI, Barchetti et al50 found equivalent sensitivity,
specificity, accuracy, PPV, and NPV. Schuster et al,52
in a comparison between 18F-fluciclovine PET/CT and
111In-capromab pendetide SPECT/CT for measures of
diagnostic utility in scans of the prostatic bed and
extraprostatic extension, found 18F-fluciclovine PET/
CT superior to 111In-capromab pendetide SPECT/CT
for sensitivity and accuracy, and without significant
differences for specificity, PPV, and NPV for scans of
the prostatic bed; and found 18F-fluciclovine PET/CT
superior to 111In-capromab pendetide SPECT/CT for
sensitvity, accuracy, PPV, and NPV, and equivalent
high specificity for scans of extraprostatic extension.
RECOMMENDATIONS
CLINICAL QUESTION 1
What is the goal of imaging in advanced prostate cancer?
Recommendation 1
Imaging is recommended for all patients with advanced
prostate cancer. See the recommendation under clinical
question 4 for specific details according to clinical scenario
(Type: evidence based, benefits outweigh harms; Evidence
quality: moderate; Strength of recommendation: strong).
Literature review, analysis, and clinical interpretation. All
the evidence obtained in this clinical practice guideline (17
systematic reviews with or without meta-analysis and 18
primary articles) supported the use of imaging in advanced
prostate cancer. The goal of imaging in advanced prostate
cancer is to facilitate the accurate and timely detection and
localization of sites of prostate cancer spread and extent,
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thus contributing to the decision-making process for
treatment planning, follow-up, and response assessment.
CLINICAL QUESTION 2
What imaging techniques are available for imaging ad-
vanced prostate cancer?
Recommendation 2
One or more of the following imaging modalities should be
used for patients with advanced prostate cancer: con-
ventional imaging (defined as CT, bone scan, and/or
prostate MRI) and/or NGI (PET, PET/CT, PET/MRI, whole-
body MRI), according to clinical scenario (Type: evidence
based, benefits outweigh harms; Evidence quality: mod-
erate; Strength of recommendation: strong).
Literature review, analysis, and clinical interpretation. Plain
film/CT. Plain film radiography relies on the differential
penetration of ionizing radiation (x-rays) through body tis-
sues of variable density to produce a 2-dimensional rep-
resentation of part of the anatomy. Its use in prostate cancer
is limited, including assessment of questionable bone scan
findings as a crude measure of bony metastasis, as well as
for rapid assessment of complications (eg, bone fractures,
pneumonia). Although large bone metastases can be vis-
ible on plain radiography, themodality plays a limited role in
achieving the presented goals of imaging in advanced
prostate cancer.
CT also relies on x-rays but takes advantage of computa-
tional postprocessing tools to generate high-resolution
3-dimensional images with exquisite anatomic detail. CT
is extensively used in staging and response assessments of
many cancers. Its main advantages are wide availability
and rapid imaging acquisition (a whole-body scan can be
performed in only a few seconds). The main limitations in
advanced prostate cancer are (1) relatively poor perfor-
mance for detection of bone metastases, as a substantial
amount of cortical destruction is necessary before bone
lesions are visible on CT, and thus early metastases are not
detected, and (2) limited assessment of lymph node me-
tastases primarily due to heavy reliance on morphologic
features (eg, size, shape, borders). CT is unable to identify
micrometastases in normal-sized nodes and unable to
accurately distinguish enlarged hyperplastic (benign) from
malignant nodes. CT is useful for the assessment of
questionable bone scan findings by demonstrating benign
conditions (trauma, degenerative changes) that result in
false-positive appearances on bone scan.
MRI. MRI produces multiplanar images without the need
for potentially harmful ionizing radiation. The strong
magnetic field in the bore of an MRI scanner causes
protons (which are naturally abundant in the human body)
to align in its direction. A radiofrequency (RF) pulse is then
applied to “spin” the body’s protons out of equilibrium.
Advanced computational tools are then used to generate
images based on the data collected, including the amount
of energy released and the time it takes protons to “realign”
with the magnetic field once the RF pulse is turned off.
Multiple imaging acquisition parameters can bemodified to
provide different “weighting” of the images (eg, T1, T2
weighting), each providing different degrees of visualization
representing different physical and biologic properties of
tissues. Compared with CT, MRI is particularly useful in the
assessment of the bone marrow, as bone marrow edema
resulting from early seeding of metastatic cancer foci, not
visible on CT, can be depicted on MRI. MR also superbly
delineates the prostatic zonal anatomy not clearly visualized
on other modalities and has thus firmly established itself as
the imaging tool of choice for the assessment of primary
prostatic tumors, using a multiparametric acquisition ap-
proach combining “anatomic” (T1- and T2-weighted) and
“functional” (DW and DCE) sequences. Limitations of MRI
include longer examination times compared with CT (pelvic
MRI typically 20-30 minutes; whole-body MRI approxi-
mately twice as long); interpretation expertise not as widely
available; and shortcomings with regard to lymph node
metastases, which also rely heavily on the same morpho-
logical features assessed with CT. Due to increasing evi-
dence of gadolinium deposition in normal tissues (eg,
brain) and lack of knowledge of the long-term health im-
plications of this finding, it is widely advocated that in-
travenous gadolinium for MRI is only used when potential
benefits outweigh risks.
Improvements in diagnostic performance for detection of
lymph node metastasis can be obtained by using nomo-
grams that consider the pretest probability based on the risk
status of the primary tumor and local staging information.51
Taken together, the general test performance of morpho-
logic imaging remains limited when histologic correlations
using template lymphadenectomy is used as the standard
of reference; a recent meta-analysis showed a CT scan
sensitivity of 42% (95% CI, 20% to 56%) and specificity of
82% (95% CI, 80% to 83%), while MRI had a sensitivity of
39% (95% CI, 19% to 56%) and specificity of 82% (95%
CI, 79% to 83%).52 Thus, morphologic CT and MRI mis-
represent nodal status and can misdirect the therapeutic
approach. There have been concerted efforts to improve
metastatic nodal detection test performance, and one
promising technique is ferumoxtran-10–enhanced MRI,
which has been shown to be able to detect microscopic
nodal disease.53 Unfortunately, lack of general commercial
availability and regulatory approval makes this method of
assessment unobtainable for most.
Bone scintigraphy. Bone scans date back to the 1960s.
Over the course of time, the technique found favor for being
relatively inexpensive and capable of whole-body assess-
ment. It involves administration of a diphosphonate, which
mimics phosphate in bone mineral and adsorbs to areas of
active bone formation, particularly around metastases
where osteoblastic activity is prominent. In some cases, it
can detect lesions not seen by CT.54-56 However, there are
22 © 2020 by American Society of Clinical Oncology
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numerous disadvantages. As the bone scan images not the
tumor itself but the body’s response to it, new bone for-
mation in response to tumor responding to therapy can
appear as a new lesion (flare response).57,58 As a result,
Prostate Cancer Working Group 3 guidelines require new
bone lesions to be seen on two consecutive scans, and new
lesions to be seen on the second scan, before progression
can be called.4 Although this approach leads to a reliable
diagnosis of bone metastases, there is an inherent delay in
establishing this due to the need for confirmatory scans. It
can also be difficult to quantify disease and therefore track
progression. A quantitative measure of involved bone, the
BSI, has been developed, and correlates with overall sur-
vival; however, its validity as a biomarker is still under
study.59 A normal bone scan produces two-dimensional
images; the three-dimensional imaging option, SPECT, is
very slow, only allowing imaging of perhaps one or two
anatomic segments of the body, such as the chest and
abdomen or abdomen and pelvis, over the course of
30 minutes (compare this with a PET scanner, which can
scan the whole body in about 15 to 20 minutes or less).
Finally, of course, a bone scan only examines the bones
and will ignore lymphatic or visceral metastases detected
by CT, MRI, or PET.
There is a large generic body of evidence for the use of bone
scan in prostate cancer. A recent meta-analysis looked
specifically at the yield of bone scintigraphy in the initial
staging of treatment-naı̈ve prostate cancer, and found
a (relatively low) yield of 3.5% with PSA# 10, 6.9% with 10,
PSA # 20, and 41.8% with PSA . 20 over 54 studies.60
Detection rate is similarly 4.1% with Gleason score # 6, 10%
with Gleason score 7, and 28.7%with Gleason score$ 8. This
suggests that the existing practice of using bone scan
specifically for initial staging of higher-risk patients (and not
using it for lower-risk patients) is sound.
PET and PET/CT. PET/CT with a variety of radiopharma-
ceuticals has received much attention in oncology over the
past several years in alleviating many of the limitations
of standard imaging methods. The radiopharmaceutical
used in PET consists of a pharmaceutical agent or “tracer”
(with biologic properties [eg, receptor binding] determining
its site of accumulation in the body) labeled with a positron
emitting radioisotope (eg, 18F [absorption half-life [t1/2],
110 minutes], 11C [t1/2, 20 minutes], 68Ga [t1/2, 68 min-
utes]), which will allow its detection with a PET camera.
FDG labeled with the isotope 18F is the most common PET
radiopharmaceutical used in oncology. FDG accumulation
in tumors is related to elevated glucose metabolism in
malignant tissue. In prostate cancer, the diagnostic per-
formance of FDG PET/CT is highly dependent on the phase
of the disease. Cumulative current evidence suggests
that FDG PET may be useful in the imaging evaluation of
extent and treatment response in metastatic castration-
resistant disease61 but not in localized prostate cancer
or in early noncastrate metastatic states. Lipogenesis
radiopharmaceuticals, including 11C-acetate and 18F- or
11C-labeled choline, have also been investigated relatively
extensively. Most studies, primarily from Europe and Japan,
with choline-based radiotracers have focused on the bio-
chemical recurrence of disease. 11C-choline was approved
in the United States in 2012 for imaging evaluation of men
with biochemical recurrence of prostate cancer after de-
finitive primary therapy. More recently in 2016, the amino
acid analog PET radiotracer 18F-fluciclovine was also ap-
proved in the United States for imaging evaluation of men
with biochemical recurrence of prostate cancer. There are
several other unapproved PET radiotracers that are actively
being investigated in the imaging evaluation of prostate
cancer. Of these radiotracers, those targeting the PSMA
receptor have receivedmuch attention with exciting results.
PSMA is a transmembrane protein expressed in the se-
cretory cells of the prostate epithelium as well as non-
prostate normal and malignant tissues. In prostate cancer,
the PSMA cleavage of vitamin B9 (folic acid) stimulates
oncogenic signaling through glutamate receptors with
downstream activation of the PI3K-Akt-mTOR signaling
pathway.62 Recent strides in synthesis of small-molecule
inhibitors of PSMA targeting the extracellular epitope of
PSMA have demonstrated major potential utility in targeted
radionuclide imaging and treatment (theranostics) of
metastatic prostate cancer. Most studies have reported on
68Ga-PSMA-11 (also known as HBED-CC). Other PSMA
binding ligands include 68Ga-PSMA imaging and therapy;
68Ga-PSMA-617; and more recently, 18F-DCFPyL and
18F-PSMA-1007.63,64 Studies have generally shown supe-
rior diagnostic performance of these radiotracers over other
relevant radiotracers in the clinical settings of intermediate-
to high-risk primary cancer, biochemical recurrence after
definitive therapy, and delineation of extent of metastatic
disease and patient eligibility for PSMA-targeted radio-
ligand therapy.22 89-Zr–labeled PSMA-targeting antibodies
and minibodies have also been reported, but practicalities
surrounding their use (eg, serial days uptake required
between administration and imaging) have resulted in their
development being largely restricted to tertiary academic
centers. It must be noted that false-negatives and false-
positives can occur with PSMA PET imaging.65 There is also
literature on proposed procedure guidelines and in-
terpretation and reporting standards.66-70 A number of
studies have reported on the major impact of PSMA PET
imaging on management of patients with prostate cancer,
although the potential influence on outcome will need
additional investigations.71-73 It is hoped that of the several
PSMA-based imaging agents that have been evaluated, the
most optimal agent will emerge that will become approved,
available, and accessible.
In general, radiocholine may be useful in this clinical setting
when PSA. 2 ng/mL (or PSA, 1 ng/mL if primary Gleason
score was 7or more), PSA doubling time is less than
6 months, or PSA velocity is greater than 2 ng/mL/year.
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Higher serum PSA level during biochemical recurrence is
generally associated with higher detectability on choline
PET, with a pooled sensitivity and specificity of 80.9% and
84.1%, respectively.74 The diagnostic performance of
18F-fluciclovine in the detection of potential lesions is
also positively associated with PSA level. In the clinically
relevant low PSA range of , 1 ng/mL in men with bio-
chemical recurrence of prostate cancer after radical
prostatectomy and off hormonal therapy, the detectability of
18F-fluciclovine PET has been reported to be 21% in
comparison with 14% with 11C-choline.48 However, in
general, these two approved radiotracers appear to be
similar in terms of lesion detectability and positive corre-
lation with serum PSA level in the clinical setting of bio-
chemically recurrent prostate cancer.75
PET/MRI. PET/CT has dominated the molecular imaging
landscape for almost two decades as it combines the sen-
sitivity and specificity of PET and the anatomic depiction of
CT. PET/MRI devices have been available since 2010 and
have been tried in a broad range of clinical settings. How-
ever, in general, they have not provided a distinct advantage
over PET/CT beyond the simultaneous acquisition of di-
agnostic PET and MRI when both tests are clinically in-
dicated. PET/MRI can be helpful in specific cases. In theory,
PET/MRI devices have several advantages over PET/CT,
including that MRI provides not only anatomy but also
functional imaging information that could increase the
specificity of PET findings, and in several regions, such as
the pelvis and bones, MRI provides additional information
that could help to characterize a lesion with PET uptake.
In the initial diagnosis and biopsy of primary prostate
cancer, numerous studies have documented an advantage
to tumor localization using a combination of PET and MRI
either at separate settings or obtained simultaneously in
PET/MRI scanners.76 The most documented advantage is
found for PSMA PET imaging in which numerous studies
document improvement in detection when combining PET
and MRI,76-81 although similar findings have been noted with
fluciclovine.82-84 Not all studies are positive, and PET/MRI with
11C-choline76,85 and one study of PSMA86 showed no ad-
vantage to PET/MRI. Occasionally, MRI is negative, but PET,
particularly with PSMA-targeted agents, is positive,78,81 aiding
in diagnosis. On the other hand, PSMA-negative primary
tumor occurs in up to 5%-10%.87 MRI also provides better
evaluation of local staging in high-risk patients, such as
extraprostatic extension or seminal vesicle invasion, than can
PET/CT due to superior spatial and contrast resolution.
In biochemical recurrence, the ability to document sites of
localized recurrence (v nodal or bony disease) is perceived
as a potential advantage for PET/MRI across many
agents.63,76,77,80 Particular benefits of MRI versus CT in-
clude absence of clip artifacts from prior node dissections
and absence of streaking artifacts from dense contrast
media within the bladder that can interfere with CT scans.
In metastatic disease, there is a perceived advantage of
whole-body MRI in detecting bone marrow changes76,81
based on the sensitivity of DW-MRI for subtle bone disease
and the high contrast of T1-weighted sequences for bone
marrow replacement. However, few studies of prostate
cancer with PET/MRI have been performed, and so there is
an absence of strong data in this setting. For metastatic
disease, whole-body imaging sequences can add consid-
erable time to the scan. Thus, such whole-body imaging is
limited to one sequence (eg, DW or T2-weighted turbo spin
echo) and/or postcontrast-enhanced MRI, which are the
most time efficient methods of evaluating the bones in
conjunction with PET. However, this causes a significant
increase in scanning time. Thus, while the increased sen-
sitivity of MRI for bone lesions could be helpful in patients
with suspectedmetastatic disease, especially with a negative
CT, clinical trial evidence is not yet available to support this.
The advantages of PET/MRI must be weighed against
multiple disadvantages. The cost of such hybrid devices is
approximately 2-3 times that of a conventional PET/CT.
Cost recovery is more difficult as the scans take longer to
obtain, reducing throughput compared with PET/CT. Addi-
tional unresolved issues include the accuracy of standardized
uptake valuemeasurements onPET/MRI comparedwith PET/
CT. Moreover, it is unclear whether it is vital that MRI and PET
be obtained simultaneously in a PET/MRI hybrid scanner or
can be obtained separately as a PET/CT and a dedicatedMRI.
It is possible that a PET/CT and a stand-alone MRI could
be performed and achieve the same advantages without
the cost of an expensive hybrid scanner.85,88
Capromab pendetide. Capromab pendetide is an 111In-
labeled antibody directed against the intracellular epi-
tope of PSMA. It is imaged using SPECT/gamma cameras
and is currently approved for initial staging of high-risk
patients and in localization of recurrence after biochemical
failure. Due to the difficulties of antibody imaging (imaging
is slow, occurring 3-5 days after injection, and burdened by
physiologic and generic antibody uptake in the bone
marrow, liver, and spleen) and the poor sensitivity due to
the intracellular localization of the epitope (making it unable
to visualize living cancer cells, particularly in bone), the
study is rarely performed at present. Among the few studies
comparing capromab pendetide directly to other imaging
modalities (no meta-analyses exist), one of 93 patients
found it inferior to the new agent fluciclovine at 10%
sensitivity and 87% specificity for extraprostatic disease
versus 55% sensitivity and 97% specificity48 for re-
currence. A similar study with 50 patients showed 10%
sensitivity and 100% specificity versus fluciclovine with
100% sensitivity and specificity for extraprostatic disease.89
An old study comparing capromab pendetide to FDG PET
and CT showed lower detection rates, although sample size
was very small (n = 21 patients).90
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CLINICAL QUESTION 3
What are the unmet needs and potential impact of imaging
according to different prostate cancer disease states?
Recommendation 3
It is recommended when choosing an imagingmodality that
disease states and clinical scenarios as outlined are taken
into consideration, as the imaging modality may guide
treatment or change clinical treatment decisions (Type:
evidence based, benefits outweigh harms; Evidence
quality: moderate; Strength of recommendation: strong).
Literature review, analysis, and clinical interpretation.
Prostate cancer frequently recurs despite negative con-
ventional imaging, presumably partly due to unrecognized
residual disease after treatment or distant metastatic dis-
ease. For this reason, there is an unmet need for accurate
diagnosis of metastatic disease for accurate staging, ap-
propriate counseling, and adequate treatment planning for
all stages of the disease. Improved and more accurate
diagnosis of disease outside of the prostate or subclinical
metastatic disease offers the potential to modulate or
change treatment. More accurate staging at initial diagnosis
could influence the local therapy offered (surgery, radio-
therapy, ablation, surveillance, and so on). For initial sur-
gery, imaging can impact planning of nerve-sparing
procedures and help to determine the extent of lympha-
denectomy. For radiotherapy, the duration of concurrent
and adjuvant ADT could be impacted as well as the extent
of radiation field (whole pelvic to include nodal drainage or
just prostate). At the time of biochemical recurrence after
local therapy, the aggressiveness and targeting of salvage
local therapy could also be impacted. For patients with
advanced disease, the timing of changes in systemic
therapies and the accurate ability to monitor response to
therapy could be impacted by more accurate imaging.
CLINICAL QUESTION 4
When and what type of imaging is appropriate in each
scenario?
Newly Diagnosed Clinically High-Risk/Very High-Risk
Localized Prostate Cancer
Recommendation 4.1. Conventional imaging negative
When conventional imaging (defined as CT, bone scan,
and/or prostate MRI) is negative in patients with a high risk
of metastatic disease, NGI (defined as PET, PET/CT, PET/
MRI, whole-body MRI) may add clinical benefit, although
prospective data are limited (Type: informal consensus,
benefits/harm ratio uncertain; Evidence quality: weak;
Strength of recommendation: moderate).
Recommendation 4.2. Conventional imaging suspicious/
equivocal
When conventional imaging is suspicious or equivocal, NGI
may be offered to patients for clarification of equivocal
findings or detection of additional sites of disease, which
could potentially alter management, although prospective
data are limited (Type: informal consensus, benefits/harm
ratio uncertain; Evidence quality: weak; Strength of rec-
ommendation: moderate).
Literature review, analysis, and clinical interpretation.
Patients presenting with high-risk, including locally ad-
vanced, prostate cancer have a high probability of harboring
metastatic disease. The prevalence of metastases is reported to
be between 30% and 50% of patients, depending on the
sensitivity of the method used for disease detection.91 Metas-
tases are most commonly located within regional pelvic lymph
nodes and in bone, with metastases located at other distant
sites being rare at this stage of the disease.
There is wide geographic variation in the availability of NGI
technologies (whole-body MRI and PET/CT), but when
available, they should be considered in the context of
a clinical trial so that generalizable data can be recorded. For
the detection of metastatic bone disease, the combination of
bone scans and CT perform suboptimally compared with
whole-body MRI and various PET/CT radiopharmaceuti-
cals.92 Systematic analyses, prospective clinical studies, and
meta-analyses have shown comparative test performance of
whole-body MRI to NaF and choline PET/CT for the skeletal
assessments in advanced prostate cancer.27,84 Shen et al27
conducted a meta-analysis of 27 studies in advanced
prostate cancer showingMRIwas superior to choline PET/CT
and bone scan for metastasis detection on a per-patient
basis. On a per-patient basis, the pooled sensitivities for bone
disease by using choline PET/CT, whole-body MRI, and
bone scan were 91% (95% CI, 83% to 96%), 97% (95% CI,
91% to 99%), and 79% (95%CI, 73% to 83%), respectively.
The pooled specificities for bone metastases detection using
choline PET/CT, whole-body MRI, and bone scan were 99%
(95% CI, 93% to 100%), 95% (95% CI, 90% to 97%), and
82% (95% CI, 78% to 85%), respectively. On a per-lesion
analysis, choline PET/CT had a higher diagnostic odds ratio
that exceeded both bone scan and bone SPECT for detecting
bone metastases. A recent meta-analysis also underscored
the usefulness of DW-MRI in detecting bone metastases. Liu
et al93 evaluated 32 studies with 1,507 patients and showed
a pooled sensitivity, specificity, and area under the curve for
DW-MRI of 95% (95%CI, 90% to 97%), 92% (95%CI, 88%
to 95%), and 0.98, respectively, on a per-patient basis, and
91% (95% CI, 87% to 94%), 94% (95% CI, 90% to 96%),
and 0.97, respectively, on a per-lesion basis. This was re-
cently confirmed by a prospective clinical trial where whole-
body MRI was compared with NaF PET/CT.84
Suspicious findings on NGI would influence treatment
decisions in patients with advanced prostate cancer and
negative conventional imaging, opening the scope for
multimodality treatment of primary and oligometastatic
disease or systemic therapy for more extensive metastatic
states. When evaluating the results of the meta-analyses,
and indeed in all studies reporting test performance of
imaging studies with any modality, it should be noted that
there are intrinsic verification biases that are particularly
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prevalent at lesion-level analyses because it is simply not
possible to obtain histopathology for every bone lesion
detected for ethical/practical clinical reasons. As a result,
most studies use combinations of imaging methods and/or
follow-up as the standards of reference.84,94 Furthermore,
as with all external imaging methods, microscopic me-
tastasis are unlikely to be detected so that true-negative
rates are difficult to ascertain.
When conventional imaging is suspicious or equivocal for
nodal or visceral lesions in castration-sensitive patients at
the highest risk of metastatic disease, there is no clear
consensus or level 1 evidence to support 18F-FDG PET/CT
and should not be routinely offered. Whole-body MRI and
NaF PET/CT may offer clinical benefit in this scenario by
redefining the true extent of disease and shifting treatment
decisions accordingly, although prospective data are lim-
ited.95 There is limited experience with other PET and ra-
dionuclide agents, such as 18F-fluciclovine and 11C- and
18F-choline, and they are not FDA approved in this setting.
There is enthusiasm for the potential added value of PSMA
PET/CT and PET/MRI for the assessment of the local and
metastatic extent of prostate cancer in this context,80,96,97
although PSMA imaging is currently not FDA approved and
should thus be only performed as part of clinical trials or
other controlled research settings.
Rising PSA After Prostatectomy and Negative
Conventional Imaging (either initial PSA undetectable
with subsequent rise or PSA never nadirs to undetectable)
Recommendation 4.3
Both disease states are indicative of potentially undetected,
residual local, locoregional, or micrometastatic disease,
and imaging options are not distinct or different between
these scenarios. The goal of therapy and the potential use
of salvage local therapies in these scenarios should guide
the choice of imaging. For men who are not candidates or
are unwilling to receive salvage local or regional therapy,
additional NGI should not be offered (Type: informal con-
sensus, benefits/harms ratio uncertain; Evidence quality: low;
Strength of recommendation: moderate).
Recommendation 4.4
For men for whom salvage radiotherapy is contemplated,
NGI should be offered (PSMA imaging [where available];
11C-choline or 18F-fluciclovine PET/CT; or PET/MRI, whole-
body MRI, and/or 18F-NaF PET/CT) as they have superior
disease detection performance characteristics and may
alter patient management (Type: evidence based, benefits
outweigh harms; Evidence quality: high; Strength of rec-
ommendation: strong).
Rising PSA After Radiotherapy and Negative
Conventional Imaging
Recommendation 4.5
For men in whom salvage local or regional therapy is not
planned or is inappropriate, there is little evidence that NGI
will alter treatment or prognosis. The role of NGI in this
scenario is unclear and should not be offered, except in the
context of an institutional review board–approved clinical
trial (Type: informal consensus, benefits/harms ratio un-
certain; Evidence quality: intermediate; Strength of rec-
ommendation: moderate).
Recommendation 4.6
For men for whom salvage local or regional therapy (eg,
salvage prostatectomy, salvage ablative therapy, or salvage
lymphadenectomy) is contemplated, there is evidence sup-
porting NGI for detection of local and/or distant sites of dis-
ease. Findings onNGI could guidemanagement in this setting
(eg, salvage local, systemic or targeted treatment of metastatic
disease, combined local and metastatic therapy). PSMA
imaging (where available), 11C-choline or 18F-fluciclovine PET/
CT or PET/MRI, whole-body MRI, and/or 18F-NaF PET/CT
have superior disease detection performance characteristics
compared with conventional imaging and alter patient
management, although data are limited (Type: evidence
based, benefits outweigh harms; Evidence quality: in-
termediate; Strength of recommendation: moderate).
Metastatic Prostate Cancer at Initial Diagnosis or After
Initial Treatment, Hormone Sensitive
Recommendation 4.7
In the initial evaluation of men presenting with hormone-
sensitive disease with demonstrable metastatic disease on
conventional imaging, there is a potential role for NGI to
clarify the burden of disease and potentially shift the treat-
ment intent from multimodality management of oligometa-
static disease to systemic anticancer therapy alone or in
combination with targeted therapy for palliative purposes,
but prospective data are limited (Type: informal consensus,
benefits/harms ratio uncertain; Evidence quality: in-
termediate; Strength of recommendation: moderate).
Recommendation 4.8. Nonmetastatic CRPC
For men with nonmetastatic CRPC, NGI can be offered only
if a change in the clinical care is contemplated. Assuming
patients have received or are ineligible for local salvage
treatment options, NGI may clarify the presence or absence
of metastatic disease, but the data on detection capabilities
of NGI in this setting and impact on management are limited
(Type: consensus, benefits/harms ratio uncertain; Evidence
quality: weak; Strength of recommendation: moderate).
Recommendation 4.9. Metastatic CRPC (PSA progression)
As recommended by the Prostate Cancer Working Group 3
consensus statements,98 PSA progression alone for men on
treatment of metastatic CRPC should not be the sole reason
to change therapy. Conventional imaging can be used for
initial evaluation of PSA progression and should be continued
to facilitate changes/comparisons and serially to assess for
development of radiographic progression. (Type: informal
consensus, benefits/harms ratio uncertain; Evidence quality:
intermediate; Strength of recommendation: strong).
26 © 2020 by American Society of Clinical Oncology
Trabulsi et al
Downloaded from ascopubs.org by Queen's University Belfast on February 3, 2020 from 143.117.193.021
Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
Recommendation 4.10
The use of NGI in this cohort is unclear, with a paucity of
prospective data. When a change in clinical care is con-
templated, in an individualized manner, and there is a high
clinical suspicion of subclinical metastasis despite negative
conventional imaging, the use of NGI could be contem-
plated, especially in the setting of a clinical trial (Type: in-
formal consensus, benefits/harms ratio uncertain; Evidence
quality: insufficient; Strength of recommendation: weak).
Recommendation 4.11. Radiographic progression on con-
ventional imaging
In men with metastatic CRPC with clear evidence of ra-
diographic progression on conventional imaging while on
systemic therapy, NGI should not be routinely offered. NGI
may play a role if performed at baseline to facilitate com-
parison of imaging findings/extent of progression of disease
(Type: consensus, benefits/harms ratio uncertain; Evi-
dence quality: insufficient; Strength of recommendation:
moderate).
DISCUSSION
There has been tremendous excitement in the prostate
cancer community for advanced, molecular-based, NGI.
This is driven in large part by the biology of the disease as
well as by the clinical need to accurately stage patients and
assess the burden and extent of disease. Prostate cancer
categorization utilizes the clinical disease states model,
which is determined by tumor characteristics, radiographic
extent of disease, and prior therapies administered, making
accurate imaging paramount. The anatomy of the prostate
in the pelvis, with the very delicate surrounding structures
that control crucial bodily functions (urinary, rectal, and
sexual function), makes accurate assessment of extent of
local disease crucial. For men whose disease is no longer
localized and widespread, aggressive local therapy that will
adversely impact urinary, sexual, and bowel domains could
carry unacceptably high adverse effects with detriment to
quality of life. Conversely, aggressive local therapy that
could offer potential cure may be inappropriately withheld
when conventional clinical parameters, such as PSA or
Gleason score, deem a man high risk, for which NGI could
indicate organ-confined disease without evidence of distant
disease. The availability and clinical utility of PSA, an ex-
quisitely sensitive serum-based tumor marker for prostate
cancer, can add to the complexity of accurately de-
termining the disease state, again highlighting the impor-
tance of accurate imaging. Following the disease states
model, we have drafted our recommendations utilizing
common clinical scenarios in the natural history of prostate
cancer treatment, for which appropriate use of imaging can
be categorized.
The primary driver for obtaining imaging should be when
clinicians and patients are at a treatment nexus; therefore,
imaging studies that will not impact or inform treatment
decisions should be minimized. The urge or instinct to
order multiple imaging modalities is common for solid tu-
mor oncology, particularly to accurately assess burden of
disease and risk to the patient. The overuse of imaging,
especially NGI, does carry risks of increased cost, in-
appropriate ionizing radiation delivery to patients, and the
risk of false-positive findings, which generate fear and
anxiety for patients and clinicians as well as generate other
unnecessary interventions.
As previously stated, the decision for NGI for patients ex-
periencing biochemical recurrence is predicated on the
potential treatment plan. If no additional salvage therapy,
such as salvage radical prostatectomy, salvage radiother-
apy, salvage ablative therapy (eg, cryotherapy, high-
intensity focused ultrasound therapy), or salvage lympha-
denectomy, is planned because of patient concerns or
preference due to potential adverse effects or medical
comorbidities that preclude aggressive therapy, then the
utilization and benefit of NGI is questionable.
In the arena of PET-directed imaging, there are multiple
compounds in use that have been proposed, including
small-molecule agents targeting PSMA as well as amino
acid and fatty acid agents. There is a paucity of comparative
data among these agents, and accurate comparisons be-
tween them are limited. This is an area in the future where
prospective comparative studies would clarify the appro-
priate role and utility of these agents.
Similarly, there have been multiple isotopes in use with
varying half-lives and source generators. These include
primarily 11C, 18F, and 68Ga, with several smaller studies
investigating other isotopes. Comparative studies to assess
the accuracy of imaging different isotopes are also lacking,
and the clinical implementation of specific isotopes have
been driven mostly by half-life, ease of distribution, and
method of isotope generation. This is another area of op-
portunity for analysis in the future.
In reviewing the published literature, there is a paucity of
well-designed prospective studies in NGI for prostate
cancer, and this Guideline Panel endeavored to create
a reasonable, evidence-based, malleable framework to
guide the optimal use of imaging in patients with advanced
prostate cancer. As technology evolves and current and
future prospective evaluations of NGI become available, we
expect that these guidelines may require updates or
changes in the future.
The Advanced Prostate Cancer Consensus Conference
2017 guideline99 recommended that imaging be performed
at baseline, PSA nadir, and progression at least in patients
with the usual presentation of metastatic hormone-sensitive
prostate cancer. Imaging should also be performed in
between these dates if there are additional clinical needs.
Additionally, regular imaging monitoring of disease is
recommended if there is a likelihood of aggressive variant
prostate cancer (including small-cell and neuroendocrine)
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when the following clinical/pathologic/imaging features are
present100:
• Exclusively visceral metastases
• Radiographically predominant lytic bone metastases
by plain x-ray or CT scan
• Bulky ($ 5 cm) lymphadenopathy or bulky ($ 5 cm)
high-grade (Gleason $ 8) tumor mass in prostate/
pelvis
• Low PSA (# 10 ng/mL) at initial presentation (prior to
ADT or at symptomatic progression in the castrate
setting) plus high-volume ($ 20) bone metastases
• Presence of neuroendocrine markers on histology or in
serum; marked hypercalcemia
• Raised carcinoembryonic antigen
• Short interval (# 6 months) to androgen-independent
progression following the initiation of hormonal therapy
with or without the presence of neuroendocrine
markers
SPECIAL COMMENTARY
The recommendations provided are based on systematic
literature review and do not specifically address the lack of
universal availability of NGI modalities worldwide. Approval
and payment for many NGI modalities have been ham-
pered in the United States and other countries, both re-
gionally and nationally, with significant angst for both
patients and clinicians. This aspect is fluid and evolving,
and availability should be considered when clinicians and
patients pursue specific NGI modalities. As more evidence
is presented that support the clinical utility of these imaging
modalities, the availability of these tests may widen in the
future.
PATIENT AND CLINICIAN COMMUNICATION
In panel discussions, there was robust discussion about
patient counseling and concerns for false-positive and
false-negative imaging results for conventional imaging as
well as for NGI. It should be acknowledged that improved
sensitivity for detection of low-volume metastatic disease
may not be clinically relevant if there is a high false-positive
rate, with attendant secondary testing, biopsy, and so forth.
Additionally, there was also agreement that patients should
be counseled on the life-long risk of ionizing radiation that
NGI testing, particularly involving CT (eg, PET/CT), carry
with the risk of subsequent malignancies. While perhaps
not relevant for patients with advanced prostate cancer who
have exhausted multiple lines of therapy, this does pertain
to men in earlier disease states. Awareness of these issues
with careful and deliberate communication is recom-
mended between clinicians and patients.
For recommendations and strategies to optimize patient-
clinician communication, see Patient-Clinician Communi-
cation: American Society of Clinical Oncology Consensus
Guideline.101
HEALTH DISPARITIES
Although ASCO clinical practice guidelines represent ex-
pert recommendations on the best practices in disease
management to provide the highest level of cancer care, it is
important to note that many patients have limited access to
medical care. Racial and ethnic disparities in health care
contribute significantly to this problem in the United States.
Patients with cancer who are members of racial/ethnic
minorities suffer disproportionately from comorbidities,
experience more substantial obstacles to receiving care,
are more likely to be uninsured, and are at greater risk of
receiving care of poor quality than other Americans.102-105
Many other patients lack access to care because of their
geographic location and distance from appropriate treat-
ment facilities. Awareness of these disparities in access to
care should be considered in the context of this clinical
practice guideline, and health care providers should strive
to deliver the highest level of cancer care to these vul-
nerable populations.
MULTIPLE CHRONIC CONDITIONS
Creating evidence-based recommendations to inform
treatment of patients with additional chronic conditions,
a situation in which the patient may have two or more such
conditions—referred to as multiple chronic conditions
(MCCs)—is challenging. Patients with MCCs are a complex
and heterogeneous population, making it difficult to ac-
count for all of the possible permutations to develop specific
recommendations for care. In addition, the best available
evidence for treating index conditions, such as cancer, is
often from clinical trials whose study selection criteria may
exclude these patients to avoid potential interaction effects
or confounding of results associated with MCCs. As a result,
the reliability of outcome data from these studies may be
limited, thereby creating constraints for expert groups to
make recommendations for care in this heterogeneous
patient population.
As many patients for whom guideline recommendations
apply present with MCCs, any treatment plan needs to take
into account the complexity and uncertainty created by the
presence of MCCs and highlights the importance of shared
decision making regarding guideline use and imple-
mentation. Therefore, in consideration of recommended
care for the target index condition, clinicians should review
all other chronic conditions present in the patient and take
those conditions into account when formulating the treat-
ment and follow-up plan.
For patients with prostate cancer under 65 years of age, the
10 most common comorbidities are (in descending order)
hypertension, hyperlipidemia, diabetes, ischemic heart
disease, anemia, arthritis, chronic kidney disease, de-
pression, chronic obstructive pulmonary disease (COPD),
and heart failure. For patients with prostate cancer over
65 years of age, the 10 most common comorbidities are (in
28 © 2020 by American Society of Clinical Oncology
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descending order) hypertension, hyperlipidemia, ischemic
heart disease, anemia, diabetes, arthritis, chronic kidney
disease, cataract, heart failure, and COPD.
In light of these considerations, practice guidelines should
provide information on how to apply the recommendations
for patients with MCCs, perhaps as a qualifying statement
for recommended care. This may mean that some or all of
the recommended care options are modified or not applied,
as determined by best practice in consideration of
any MCC.
Men with advanced prostate cancer commonly may have
medical comorbidities and chronic kidney disease, which
preclude the use of iodinated contrast or gadolinium. This
may limit the applicability and administration of conven-
tional and NGI in specific patient populations. An in-
dividualized approach is recommended to account for
these conditions.
COST IMPLICATIONS
There has been a dramatic expansion in health care ex-
penditures over the past 2 decades, and imaging tech-
nologies represent one of the fastest growing areas of health
care spending. In particular, advanced imaging technol-
ogies, such as MRI, CT, and PET, may drive as much as
50% of these increased costs.106 Policy levers may be able
to control some of these spiraling costs107; however, in-
creasingly, individuals diagnosed with cancer are required
to pay a larger proportion of their treatment costs.108-110
These higher out-of-pocket payments may represent
a barrier to the initiation of and adherence to recommended
cancer treatments.111-113 Therefore, a tailored discussion of
potential diagnostic and treatment costs is an important
component of shared treatment decision making.114 When
feasible, clinicians should counsel patients regarding the
use of less expensive alternatives for diagnosis and treat-
ment when there is clinical equipoise or rapidly evolving
therapy options, such as the case with imaging for ad-
vanced prostate cancer.114
Importantly, there is considerable heterogeneity in health
care costs for diagnostic imaging. Variation in expenditure
may be related to region, payer, hospital system, negotiated
contracts, insurance status, or severity of illness, and this
variability precludes a systematic and generalizable eval-
uation.115 With regard to advanced imaging modalities in
particular, there is substantial variation in organizational
costs related to isotope procurement from external sources
(18F-choline), possible cyclotron expenses (11C-choline),
generator expenses, and radiopharmacy (68Ga-PSMA) as
well as the direct costs of disposable equipment and
indirect costs of physicians, technologists, and radio-
pharmacists.116 When discussing financial issues sur-
rounding care delivery, patients should be made aware of
any economic counseling services available to address
this very complex landscape.114
Given the recent and rapid expansion of imaging modalities
for advanced prostate cancer, there are no exhaustive
comparative effectiveness analyses that encompass each
of the techniques described in this guideline. There are
data that suggest that advanced imaging modalities can
be cost effective for patients with cancer, in general,
particularly when used for monitoring therapy, staging,
or diagnosis, rather than screening.117 A formal cost-
effectiveness evaluation of advanced imaging for patients
with prostate cancer will have to balance the important
patient-level factors specifically associated with a prostate
cancer diagnosis, such as the relative longevity associated
with a high-risk prostate cancer diagnosis, the loss of
physical productivity, and the substantial costs associated
with skeletal-related events.118-120
As this field continues to rapidly expand and we endeavor to
clarify the most sensitive and cost-effective imaging mo-
dality for advanced prostate cancer, it will be important to
consider the potential impact of the inevitable re-
gionalization and the subsequent access challenges that
these emerging, advanced technologies will likely create.
This will be a particularly important consideration for
populations at already increased risk of health care
disparities.
EXTERNAL REVIEW AND OPEN COMMENT
The draft recommendations were released to the public
for open comment from February 22, 2019, through
March 8, 2019. Response categories of “Agree as
written,” “Agree with suggested modifications,” and
“Disagree. See comments” were captured for every
proposed recommendation, with 13 submissions re-
ceived. A total of 100% of the 13 respondents either
agreed or agreed with slight modifications to the rec-
ommendations, and 0% of the respondents disagreed.
Expert Panel members reviewed comments from all
sources and determined whether to maintain original
draft recommendations, revise with minor language
changes, or consider major recommendation revisions.
All changes were incorporated prior to CPGC review and
approval.
The draft was submitted to 2 external reviewers with
content expertise. It was rated as high quality, and it was
agreed that it would be useful in practice. Comments re-
ceived assisted in presenting the strength of the evidence
that supported each of the recommendations and helped to
contextualize this guideline in relation to other ASCO
guidelines within this disease site. Review comments were
reviewed by the Expert Panel and integrated into the final
manuscript before approval by the CPGC.
GUIDELINE IMPLEMENTATION
ASCO guidelines are developed for implementation
across health settings. Barriers to implementation in-
clude the need to increase awareness of the guideline
Journal of Clinical Oncology 29
Optimum Imaging Strategies for Advanced Prostate Cancer Guideline
Downloaded from ascopubs.org by Queen's University Belfast on February 3, 2020 from 143.117.193.021
Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
recommendations among frontline practitioners and sur-
vivors of cancer and caregivers as well as to provide
adequate services in the face of limited resources. The
guideline Bottom Line Box was designed to facilitate
implementation of recommendations. This guideline will be
distributed widely through the ASCO Practice Guideline
Implementation Network. ASCO guidelines are posted on
the ASCO web site and most often published in JCO and
a summary in Journal of Oncology Practice.
LIMITATIONS OF THE RESEARCH AND FUTURE RESEARCH
This guideline is based on the best available evidence
regarding the use of imaging in advanced prostate
cancer. However, it is recognized that there are gaps in
knowledge related to insufficiency or absence of data in
various scenarios related to this condition. Specifically,
there are limited data on head-to-head comparisons of
diagnostic performance of different imaging modalities
or different radiopharmaceutical agents in the same
patient population. Also, while there is evidence of
feasibility of use and change in management as a result
of imaging findings, none of the imaging modalities show
prospective evidence conferring patient benefit in terms
of outcomes (ie, how patients feel, function, or survive).
These should be areas for focused future research. Fi-
nally, some of the agents that have been shown to have
higher detection capabilities in prostate cancer (eg,
PSMA) do not have regulatory approval for use in the
United States.
ADDITIONAL RESOURCES
More information, including a Data Supplement with
additional evidence tables, slide sets, and clinical tools
and resources, is available at www.asco.org/genitourinary-
cancer-guidelines. Patient information is available at
www.cancer.net.
RELATED ASCO GUIDELINES
• Integration of Palliative Care Into Standard On-
cology Practice121 (http://ascopubs.org/doi/
10.1200/JCO.2016.70.1474)
• Patient-Clinician Communication101 (http://
ascopubs.org/doi/10.1200/JCO.2017.75.2311)
• Hypofractionated Radiation Therapy for Local-
ized Prostate Cancer122 (http://ascopubs.org/doi/
10.1200/JCO.18.01097)
• Clinically Localized Prostate Cancer123 (http://
ascopubs.org/doi/10.1200/JCO.18.00606)
• Optimizing Anticancer Therapy in Metastatic
Noncastrate Prostate Cancer124 (http://
ascopubs.org/doi/10.1200/JCO.2018.78.0619)
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